CancerNetwork Members: Login | Register
Become a fan on  Facebook  Add us on  Google Plus Follow us on  Twitter Join us on LinkedIn Sign up for our Newsletters Subscribe to our RSS Feed

 

CancerNetwork SearchMedica Medline Drugs

Powered by SearchMedica

 
PUBLICATIONS
NEWS
PODCASTS
TOPICS
BLOGS
NURSES
PATIENTS
JOBS
CONFERENCES
CME
SUPPLEMENTS
 

Home » Practice and Policy

ONCOLOGY. Vol. 26 No. 11
COMMENTARY 

The War on Waste

By Richard A. Cooper, MD1 | November 15, 2012
1Center for the Future of the Health Care Workforce, New York Institute of Technology, New York, New York

The article in this issue of ONCOLOGY, “The Cost of Cancer Care: Part II,”[1] has examined a broad swath of issues that are relevant not only to oncologists but to all physicians. This brief commentary will address two of these issues: why the US spends so much and what is (and is not) being done about it.

The answer to “why” is embedded in a narrative that goes something like this: The US spends twice as much on healthcare as other rich countries, yet its outcomes are among the poorest. This is due in part to higher prices and administrative costs but mainly is the result of “America’s distorted fee-for-service system that rewards quantity over quality and creates a gigantic incentive for inefficiency and waste.”[2] The Institute of Medicine (IOM) estimates this waste at about 30% of health spending—$750 billion.[3] Waste has become the mantra of healthcare reform,[3-5] and it is one of the few issues upon which Republicans and Democrats agree.

Having identified “waste” as the principal cause of high healthcare spending, policy experts have mounted a “war on waste.” In waging this war, Republicans look principally to market forces, while Democrats look to the Affordable Care Act (ACA). According to the Brookings Institution health economist Henry Aaron, the ACA includes “virtually every cost-control idea that anyone has come up with.”[6] Their intent is to redirect care from high-cost specialists to low-cost primary care physicians; to reorganize care into medical homes and accountable care organizations; to restructure reimbursement from fee-for-service to value-based purchasing and bundled payments; and to utilize incentives and penalties to reward providers who attain quality benchmarks, adhere to designated clinical guidelines, reduce hospital readmissions, adopt electronic health records, and counsel patients concerning certain preventable conditions. This entire portfolio is supported by an expansive regulatory framework and subject to future actions by an Independent Payment Advisory Board.

The ostensible goals of the “war” are to shift the emphasis from volume to value and to reduce the growth of spending. Yet few of the “cost-control ideas” were validated before being adopted, and recent studies indicate that few are achieving their stated purposes.[7-10] Indeed, some have added costs with no parallel benefit. Nonetheless, providers feel they must respond, and are rechanneling their efforts from identifying innovative solutions to satisfying regulatory standards.

Whether or not the ACA’s cost-saving goals are achieved, the “war” will decisively move the locus of control from physicians to regulators and administrators.[11] As Berwick predicted, “no longer will physicians, paternalistically committed to their patients, be the driving force in medical care. Health care has become an industry, with numerous loci of authority well beyond the doctor’s office.”[12]

It is not difficult to identify wasteful practices. Indeed, addressing them is a continuing professional responsibility. The question is whether they account for as much as 30% of healthcare spending. While several authoritative “guesstimates” claim that they do,[4,5,13] the quantitative basis for believing so comes from studies of geographic variation in healthcare by Dartmouth Atlas researchers, who identified a portion of the variation that is “unexplained,” attributed it to waste and inefficiency, and pegged it at 30% of spending.[14,15] However, although widely cited, these studies are deeply flawed.[16,17] Indeed, in an op-ed in The Washington Post, I warned that the Dartmouth Atlas was the “wrong map for healthcare reform.”[18]

What, then, explains the “unexplained” variation? The answer resides in population health.[17] It is well known that disease prevalence is greatest among individuals who are poor, poorly educated, often minorities, and usually residing in poor neighborhoods. Healthcare utilization among them is much greater than in wealthy populations. Yet their outcomes are poorer. Moreover, because poverty is geographic, their increased utilization follows geographic patterns.[17]

Manhattan in New York City is a good example. Because healthcare utilization there is among the nation’s highest, Manhattan is seen as wasteful and inefficient. But it is a patch-quilt of wealth and poverty. Utilization in the low-income Bowery is double the rate of the affluent Upper East Side and Upper West Side, and utilization in Harlem, the poorest area, is more than triple (unpublished data). Without either, Manhattan’s utilization is among the lowest in the nation, lower even than Grand Junction, Colorado, whose healthcare system was held out by President Obama as a model for the nation. But like Grand Junction, the Upper East Side and Upper West Side of Manhattan have few African Americans and no poverty ghettos.

How much does the extra care in poor neighborhoods add to overall utilization costs within a region? The best estimate is 20% to 25%.[17] Yet, tragically, this fact is ignored—indeed, denied. For example, Dartmouth researchers mock the fact that “some physicians believe their hospitals or regions spend more because their patients are sicker and poorer” and declare, “regional differences in poverty explain almost none of the variation.”[19] In a similar manner, Nicholas Kristof, a columnist for The New York Times and an advocate for the poor globally, labeled as “opponents of health care reform” those who attributed poor outcomes to “America’s large underclass.”[20] In fact, poverty explains virtually all of the regional differences in utilization, and “America’s large underclass” accounts for virtually all of the differences in outcomes between the US and other nations.

Real healthcare reform would address these socioeconomic realities. Instead, the US is waging a regulatory “war” on exaggerated measures of waste, one that shows little promise of reducing costs or increasing quality but will assuredly crush “needed innovation by practicing physicians, who best understand the delivery of care.”[1] Moreover, because there are no risk adjusters for poverty, physicians whose low-income patients fail to meet federal utilization and quality norms will suffer financially, and hospitals whose poor patients have high readmission rates will be penalized. All the while, the “war on waste” will distract policymakers from building the social infrastructure that could lower the high healthcare costs of poverty. These are no ordinary times. For the first time, physicians and their patients are caught in the crosshairs of the “war on waste.”

Financial Disclosure: The author has no significant financial interest or other relationship with the manufacturers of any products or providers of any service mentioned in this article.

 

Join the Conversation

Want to join the conversation? If you're a healthcare professional, we'd like to hear your comments. Just sign in or register today to become part of our growing, online community.

This commentary refers to the following article

The Cost of Cancer Care: Part II





References

1. Eagle D. The cost of cancer care: Part II. Oncology (Williston Park). 2012:26:1104-18.

2. Brooks D. Modesty and audacity. The New York Times, June 28, 2012. Available from: http://www.nytimes.com/2012/06/29/opinion/modesty-and-audacity.html. Accessed October 18, 2012.

3. Institute of Medicine (IOM). The Healthcare imperative: lowering costs and improving outcomes: workshop series summary. Washington, DC: The National Academies Press, 2010; p 51.

4. Berwick DM, Hackbarth AD. Eliminating waste in US health care. JAMA. 2012;307:1513-16.

5. Boat TF, Chao SM, O’Neill PH. From waste to value in health care. JAMA. 2008;299:568-71.

6. Aaron HJ. Rationing health care to control costs (Letter). The New York Times. September 24, 2012; p A22.

7. Colla CH, Wennberg DE, Meara E, et al. Spending differences associated with the Medicare physician group practice demonstration. JAMA. 2012;308:1015-23. 

8. Nocon RS, Sharma R, Birnberg JM, et al. Association between patient-centered medical home rating and operating cost at federally funded health centers. JAMA. 2012;308:60-6.

9. Soumerai S, Koppel R. A major glitch for digitized health-care records. The Wall Street Journal. September 18, 2012; p A17. 

10. Jha AK, Joynt KE, Orav EJ, Epstein AM. The long-term effect of premier pay for performance on patient outcomes. N Engl J Med. 2012;366:1606-15.

11. Cooper RA, Straus DJ. Clinical guidelines, the politics of value and the practice of medicine: physicians at the crossroads. J Oncol Pract. 2012:8:233-35.

12. Brennan TA, Berwick DM. New rules: regulation, markets, and the quality of American health care. San Francisco: Jossey-Bass; 1996.

13. Lawrence D. Bridging the quality chasm. In: Building a better delivery system: a new engineering/health care partnership, part 2. Reid PR, Compton WD, Grossman JH, Fanjiang G, eds. Washington, DC: National Academies Press; 2005. Available from: http://www.nationalacademies.org/onpi/030909643X.pdf. Accessed October 18, 2012.

14. Wennberg JE, Fisher ES, Skinner JS. Geography and the debate over Medicare reform. Health Affairs. 2002;21:w96-114.

15. Fisher ES, Wennberg DE, Stukel TA, et al. The implications of regional variations in Medicare spending, part 1: the content, quality, and accessibility of care. Ann Intern Med. 2003;38:273-87.

16. Cooper RA. Geographic variation in health care and the affluence-poverty nexus. Adv Surg. 2011;45:63-82.

17. Cooper RA, Cooper MA, McGinley EL, et al. Poverty, wealth and health care utilization: a geographic assessment. J Urban Health 2012:89:828-47.

18. Cooper RA. The wrong map for health care reform. The Washington Post. Sept 11, 2009. Available from: http://www.washingtonpost.com/wp-dyn/content/article/2009/09/10/AR2009091003405.html. Accessed October 18, 2012.

19. Sutherland JM, Fisher ES, Skinner JS. Getting past denial—the high cost of health care in the United States. N Engl J Med. 2009;361:1227-30.

20. Kristof ND. Access, access, access. The New York Times. March 18, 2010. Available from: http://www.nytimes.com/2010/03/18/opinion/18kristof.html. Accessed October 18, 2012.


 
RELATED CONTENT

Supreme Court Ruling Invalidates Myriad’s BRCA Gene Patents
June 14, 2013
How the Sequester Cuts Are Harming Oncology
ONCOLOGY,  May 15, 2013
Are CML Drugs Priced Out of Reach?
May 2, 2013
US Cancer Organizations Say Medicare Cuts Will Negatively Impact Cancer Patients
April 29, 2013
Oncologists Hope Congress Will Exempt Cancer Drugs From Sequester Cuts
April 27, 2013
 
TOPIC INDEX

Cancer Types

 
  • Breast
  • Breast (HER2+)
  • Breast (Triple-Negative)
  • CML
  • Colorectal
  • Gastrointestinal
  • GIST
  • Genitourinary
  • Gynecologic
  • Head & Neck
  • Hematology
  • Kidney (Renal Cell)
  • Leukemia
  • Lung
  • Lymphoma
  • Melanoma
  • Multiple Myeloma
  • Ovarian
  • Prostate
  • Sarcoma

Supportive Care

More Topics

  • Bone Metastases
  • End-of-Life Care
  • Palliative Care
  • Ethics in Oncology
  • Practice Management
  • Practice & Policy


All Topics 


 
   SEARCH MEDICA RX
   Browse drugs by name:
A B C D E F G H I J
K L M N O P Q R S T
U V W X Y Z All      
   Search for drugs:
Search

 

 
FROM PHYSICIANS PRACTICE
Key Differences between FQHCs and RHCs
Chastity Werner, RHIT, June 13, 2013
FQHCs and RHCs take up a unique niche among physician practices. And that affects compensation and billing.
Improving Care Coordination in Your Practice
Susanne Madden,  June 12, 2013
Practices are feverishly working to control the rising costs of healthcare - effective care coordination can help.
Refunding Overpayments: Two Options for Medical Practices
Ericka L. Adler,  June 12, 2013
Medicare and Medicaid providers must return overpayments once identified. Here are two different refund approaches for practices to consider when necessary.
Four Easy Ways to Boost Patient Time of Service Collections
Aubrey Westgate,  June 12, 2013
Simple ways your medical practice staff can increase the likelihood patients will pay when presenting for appointments.
iPad Alternatives for Mobile Physicians
Marisa Torrieri, June 11, 2013
As more physicians are seeing the merits of media tablets, the market is expanding, too.
 

 

 
MOST POPULAR
  • Most Popular
  • Most Emailed
  • Most Recent
  • Dermatologic Adverse Events Associated With Targeted Therapies
  • Papillary Thyroid Carcinoma
  • Robotic-Assisted Radical Prostatectomy: Who Is Benefiting?
  • ASCO: Long-Term Tamoxifen Benefit for Breast Cancer Confirmed
  • Lower Back Pain in an Elderly Man With a History of Localized Prostate Cancer
  • Cannabis Linked to Decreased Bladder Cancer Risk
  • Breast Cancer Screening, Risk, and Options for High-Risk Women
  • Recurrent Epithelial Ovarian Cancer: An Update on Treatment
  • Rising PSA Level in a 46-Year-Old Man
  • ASCO: Long-Term Tamoxifen Benefit for Breast Cancer Confirmed
  • Bladder Cancer Recurrence High, Better Follow-Up Care Needed
  • ASCO: Post-Surgery Surveillance Found Safe in Seminoma
  • Fertility Preservation in Women With Breast Cancer: Challenges and Opportunities
  • Addressing Fertility Concerns in Women Diagnosed With Breast Cancer: Will Serial Reserve Screening Help?
  • Postmenopausal Hormone Receptor–Positive Advanced Breast Cancer
Click here to subscribe to our newsletter
 
COMMENTS
  • Most Commented
  • Most Recent
  • 50 Shades of Pink—And Why It Helps to Know the Difference
  • Preventing Exposure to Hazardous Drugs
  • ASCO: Vinegar Screening Significantly Reduces Cervical Cancer Mortality
  • ASCO: Sulforaphane in Prostate Cancer Found Worthy of Further Investigation
  • Study: Recurrent Heartburn Ups Risk for Throat Cancer
  • HER2-Directed Therapy for Metastatic Breast Cancer
  • Accelerated Partial-Breast Irradiation: The Current State of Our Knowledge
  • It’s Time for Clinicians to Reconsider Their Proscription Against the Use of Soyfoods by Breast Cancer Patients
  • 50 Shades of Pink—And Why It Helps to Know the Difference
  • ASCO: No Benefit From Avastin in Newly Diagnosed Glioblastoma
Click here to subscribe to our newsletter


CancerNetwork on Facebook
 
SearchMedica Search Result

Find peer-reviewed literature and websites for practicing medical professionals

CME on Health Care
Evidence on Health Care
Guidelines on Health Care
Patient Education on Health Care
Clinical Trials on Health Care
Practical Articles on Health Care
Research and Reviews on Health Care
All "Health Care" results


CancerNetwork | ConsultantLive | Diagnostic Imaging | Musculoskeletal Network | OBGYN.net | PediatricsConsultantLive |
Physicians Practice | Psychiatric Times | SearchMedica | Medical Resources

© 1996 - 2013 UBM Medica LLC, a UBM company
Privacy Statement - Terms of Service - Advertising Information - Editorial Policy Statement - UBM Medica Network Privacy Policy